|Bid||0.1050 x N/A|
|Ask||0.1300 x N/A|
|Day's range||0.1150 - 0.1150|
|52-week range||0.0400 - 0.1850|
|Beta (5Y monthly)||2.54|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
U3O8 Corp. (NEX: UWE.H), (“U3O8” or the “Company”) reports that, further to the press release dated March 30, 2020, announcing that the Company would not be proceeding with the reverse takeover described in its March 2, 2020 press release, the Company’s submission to TSX Venture Exchange for the lifting of the halt on trading of the Company’s shares, has been accepted. Subject to final regulatory approval, trading of the Company’s common shares will resume on the NEX on opening of the market today, April 27, 2020. Company will continue to evaluate acquisition opportunities and other business opportunities that may become available to it in the context of the market, and of a strengthening uranium price, with a view to completing a reactivation transaction in accordance with the policies of the TSX Venture Exchange.
U3O8 Corp. (NEX: UWE.H), (OTCQB: UWEFF) (“U3O8” or the “Company”) announces that, further to the press release dated March 2, 2020, the letter of intent (“LOI”) between the Company and Diagnostic Lab Corporation, Inc. to negotiate and complete a proposed reactivation transaction, has been terminated in accordance with the provisions of the LOI, and the transaction contemplated therein will not proceed. The Company will continue to evaluate other acquisition opportunities with a view to completing a reactivation transaction in accordance with the policies of the TSX Venture Exchange. Submissions are being made to the TSX Venture Exchange to allow for the resumption of trading.